Artax Biopharma Inc’s Post

At Artax Biopharma, we are developing first-in-class Nck modulators to treat T cell mediated autoimmune disease such as #psoriasis, #atopicdermatitis, and more. We're excited by the progress we've been making in the development of our first novel mechanism, AX-158, as we rapidly approach results from our phase 2 trials for psoriasis treatment with first results expected in December 2024. We are simultaneously developing additional Nck modulator candidates for #autoimmunediseases with AX-194 undergoing preclinical testing to enter Phase 1 trials. Learn more about our candidate pipeline here: https://lnkd.in/eqq3eSTK #clinincaltrials #immunology

Forbion is thrilled to support portfolio company SynOx Therapeutics as it advances in the fight against Tenosynovial Giant Cell Tumour (TGCT), a rare and debilitating disease. The company announced the completion of an extension to its Series B financing, bringing the total raised to an impressive $92 million. This funding is advancing the TANGENT study, SynOx’s pivotal Phase 3 clinical trial for emactuzumab, a CSF-1 receptor (CSF-1R) inhibiting monoclonal antibody that has the potential to be best-in-class for TGCT treatment. The TANGENT study has officially dosed its first patients and will be conducted globally across multiple centers. With a rigorous, randomized, double-blind, placebo-controlled design, the trial will evaluate overall response rate, functional and quality of life improvements, tumour volume impact, and response duration in approximately 130 patients. We are inspired by SynOx’s commitment to transforming TGCT treatment and look forward to sharing updates from this promising trial. For more details about TANGENT go to ClinicalTrials.gov identifier: NCT05417789 Click on the following link to learn more: https://lnkd.in/eHANaNMc #Forbion #SynOxTherapeutics #SeriesB #TGCT #Biotech #ClinicalTrials #HealthcareInnovation #lifesciences #biotech Dirk Kersten Audrey Cacaly

📢 Promising Drug Blocks Epstein Barr Virus Diseases 🌟 Hornet Therapeutics, a spin-out from the University of Basel, has published first data on its preclinical IDO1 blocker HTX-201. They aim to start clinical tests within the next 12 to 18 months to target post-transplant lymphoproliferative disease. 🏥 This small molecule drug has the potential to block a target used by the Epstein Barr virus to cause diseases. 🦠 #BioprocessUpdates #HornetTherapeutics #EBV #diseaseblocker #HTX201 #clinicaltests #posttransplantlymphoproliferativedisease #smallmoleculedrug #EpsteinBarrvirus #preclinicaldata #UniversityofBasel #virusrelateddiseases #antiviraltherapy #medicalresearch #transplantmedicine #innovationinmedicine ▷ Read the full article here: 📎 https://lnkd.in/dSTEbP3u

📣 Excited to announce that Scientist.com will be hosting a webinar featuring GemPharmatech and BioRay Pharmaceutical at the end of this month! This webinar will cover #ADCs and the humanized #MouseModels used to to evaluate them. Key topics will include: ➡️ Advantages of using humanized mouse models to evaluate ADCs ➡️ Applications of humanized mice to evaluate ADCs in autoimmune disease models ➡️ The design and screening of the Linker-Payloads of Bioray’s Immune modulating ADC (ImADCTM) 🔻🔻 Make sure to sign up here 🔻🔻 #autoimmunedisease #antibodydrugconjugates #biopharma #scientist

You are invited to our joint webinar with BioRay through Scientist.com on how humanized mouse models have been supporting the development of ADC drugs for treating autoimmune diseases!

#Congratulations 🎊 to #BIAMember Accession Therapeutics Limited who have filed an application for a first-in-human trial of TROCEPT-01 ➡️ https://ow.ly/eF6L50TmbVk TROCEPT-01 is a leading #Anticancer #immunotherapy, designed to showcase the program in solid tumours and provide clinical validation of the #TROCEPT platform 👏 Their team focused on getting TROCEPT-01, encoding a clinically validated immune #checkpoint ✅ inhibitor (ICI) transgene and with the potential to expand the success of ICIs through high tumour-localised production, to the clinic as efficiently as possible 🚀

Our portfolio company Insilico Medicine announced that following the Orphan Drug Designation (ODD) granted in June 2024, its potential best-in-class TEAD inhibitor, ISM6331, received IND approval from the US FDA in July 2024 for the treatment of mesothelioma. This marks Insilico Medicine's ninth innovative molecule to receive clinical trial approval. Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, said, "Approximately 10% of cancer patients have abnormalities in the Hippo signaling pathway. ISM6331, which targets the TEAD family, offers a new therapeutic strategy with broad potential applications, including enhancing chemotherapy efficacy, boosting tumor immunotherapy, optimizing small molecule targeting, and overcoming resistance. We are committed to leveraging AI to advance medicine and bring new hope and potential therapies to patients with rare and challenging diseases." #Biotech #Pharmaceuticals #CancerResearch #DrugDiscovery #AIDD #OrphanDrugs #QimingPortfolio #QimingHealthcare

1. PharmAust has rebranded as Neurizon Therapeutics, seeing a share price increase of approximately 90% year-to-date. 2. The company is advancing its lead drug, monepantel, now called NUZ-001, targeting neurodegenerative diseases, starting with ALS. 3. A Phase 2/3 clinical trial for NUZ-001 is set to begin in Q1 2025 as part of the HEALEY ALS Platform Trial. 4. NUZ-001 has received orphan drug designation from the FDA, providing benefits such as tax credits and market exclusivity. 5. The drug inhibits the mTOR pathway to help clear misfolded proteins in ALS, potentially slowing disease progression. 6. Early results from trials show NUZ-001 may reduce ALS symptom decline by 39% and improve patient survival rates significantly. 7. The market for ALS therapies exceeds $2 billion annually, with a high demand for effective treatments due to the lack of current cures. 8. Neurizon's strategy focuses on improving patient access, partnering with neurologists, and exploring the drug's potential for other neurodegenerative diseases.

🚀 GSK’s $300M Acquisition of Chimagen’s CMG1A46: Advancing B Cell-Driven Autoimmune Therapies 💼 On October 29, GSK’s $300M acquisition of Chimagen’s CMG1A46, a CD19/CD20 trispecific T cell engager, marked a major leap forward in tackling B cell-driven autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis. B cell depletion therapy is emerging as a highly promising approach for autoimmune conditions. 🐭At Biocytogen, we support these advancements with our drug-targeted humanized mice, engineered with human CD3E and CD3EDG genes, along with B-cell-specific targets. These models provide a human-relevant platform for assessing bispecific and trispecific antibodies in preclinical research. 💡 In addition, our proprietary RenLite® platform tackles bispecific and multispecific antibody assembly challenges, like chain mispairing, and—paired with knobs-into-holes (KIH) technology—achieves over 95% assembly success! Read more: https://lnkd.in/eSXN9GZM #AutoimmuneResearch #BCellTherapies #Biocytogen #DrugDevelopment #TCEs

Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressive lung disease with a pressing need for new therapeutics. At Aragen, we are at the forefront of developing clinically relevant models, including rodent, ex vivo, and in vitro models, to drive drug discovery for IPF.   Our bleomycin-induced pulmonary fibrosis model stands out for its reproducibility, reduced animal mortality, and consistent disease induction. This robust model has accelerated many drug candidates beyond the preclinical phase, supporting both therapeutic and prophylactic development. Click here https://lnkd.in/gRETBMWy to know more about our IPF drug development services and to partner with us to enhance your IPF drug development pipeline write to us at [email protected] #drugdevelopment #ipf #therapeutic #prophylactic #endtoendsolutions #pulmonaryfibrosis #brochure #preclinical #exvivo #invitro #lungdisease